Letter to the editor: Comment on GLP-1-based drugs and COVID-19 treatment

• Tianru Jin,
• Mingyao Liu

Affiliations

Tianru Jin

Corresponding author.; Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, M5G 1V7, Canada; Department of Physiology, Faculty of Medicine, University of Toronto, Toronto, ON, M5G 1V7, Canada; Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, ON, M5G 1V7, Canada; Toronto General Hospital Research Institute, University Health Network, Toronto, ON, M5G 1V7, Canada; Best Diabetes Centre, Faculty of Medicine, University of Toronto, Toronto, ON, M5G 1V7, Canada

Mingyao Liu

Corresponding authors.; Department of Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, M5G 1V7, Canada; Department of Physiology, Faculty of Medicine, University of Toronto, Toronto, ON, M5G 1V7, Canada; Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, ON, M5G 1V7, Canada; Toronto General Hospital Research Institute, University Health Network, Toronto, ON, M5G 1V7, Canada; Department of Surgery, Faculty of Medicine, University of Toronto, Toronto, ON, M5G 1V7, Canada